HALDRONE
LOE ApproachingNDAORALTABLET
Approved
Apr 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HALDRONE is an oral small-molecule tablet developed by Eli Lilly and approved in 1961. The mechanism of action and specific indications are not publicly documented in available records. This legacy product represents a significant portion of Eli Lilly's heritage portfolio.
LOE Approaching
With LOE approaching and moderate competitive pressure (30/100), this product likely has a contracting team focused on transition planning and competitive defense.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
HALDRONE currently has zero linked job openings, reflecting its LOE-approaching status and mature lifecycle stage. Career opportunities are concentrated in product defense, market access, and competitive positioning rather than growth or innovation roles.
Brand ManagerSenior Product Manager
Worked on HALDRONE at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.